ARN-509

All ESMO 2014 abstracts with reference to ARN-509 are listed below

• 761PD - Novel antiandrogen ARN-509 in high-risk non-metastatic (M0) castration-resistant prostate cancer (CRPC)
• 806TiP - SPARTAN - a randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) vs ADT alone in non-metastatic castration-resistant prostate cancer (M0-CRPC)